GLP-1s Tied To Lower Rates Of MS Relapse Activity, Real-World Study Shows

A U.S. database study linked GLP-1 drug exposure with lower rates of MS relapse activity and other outcomes, but cannot establish cause and effect.

AI Chatbots Can Be A Valuable Health Resource For Older Adults—if They Embrace ‘Informed Skepticism’

Research suggests older adults use AI for health information, but experts advise checking chatbot answers and protecting personal data.

Obesity In Young Adults Linked To Multiple Early Cancers

A South Korean study of 6.3 million adults found higher cancer rates with obesity in young adulthood, with associations persisting into middle age.

Birdwatching Rewires The Brain And Slows Cognitive Decline

Research links birdwatching expertise with brain organisation and activity, while care-home studies report wellbeing benefits. Long-term effects remain unclear.

14 Best Vegan Omega-3 Supplements for 2027

Compare 14 vegan omega-3 supplements by DHA and EPA content, formula, serving format, and suitability to find the right algae-based option.

Unlocking Persistent Motivation & Extreme Resilience | Ross Edgley

Ross Edgley discusses motivation, resilience and the psychology of difficult goals in a Huberman Lab podcast episode.

Medicare Will Pay $50K For Your Heart Attack. It Should Pay $100 To Prevent It.

Updated 2026 ACC/AHA guidance gives coronary calcium scans a central role in selected prevention decisions, but coverage and access remain uncertain.

15 Best Vegan Creatine Supplements for Strength and Convenience in 2027

Compare 15 vegan creatine supplements by format, serving size, testing claims, and convenience to find the right fit for your routine.

Movement Helps People Learn Complex Patterns More Effectively, Study Finds

A virtual-reality study found larger arm movements improved learning of similarity-based patterns, but not categories learned through explicit rules.

Remibrutinib Cuts Multiple Sclerosis Relapse Rates In Phase III Trials

Two Phase III trials found fewer relapses with remibrutinib than teriflunomide in relapsing MS; disability and long-term safety findings need context.